Hims (HIMS): FY26 Q3 earnings call, Nov 9, 2026
On its Nov 9, 2026 earnings call (FY26 Q3), Hims said 11 of the 19 words Kalshi listed; Parrot’s count agreed with all 19 settlements. Quotes below are at most 25 words each.
UpdatedMarkets
19 words · 11 settled yes · our count agreed on 19 of 19- Kalshi: company speakers + operator
Kalshi
| Word | Result | Our count | All speakers | Agrees | Probability | Market |
|---|---|---|---|---|---|---|
| Peptide | Yes | 12 | 15 | ✓ | 95%n=4+tx from settlement history blended with transcripts | – |
| Testosterone | Yes | 9 | 9 | ✓ | 95%n=4+tx from settlement history blended with transcripts | – |
| Wearable | Yes | 7 | 7 | ✓ | 78%n=1+tx from settlement history blended with transcripts | – |
| Australia | Yes | 7 | 7 | ✓ | 74%transcripts from the transcript model | – |
| Eucalyptus | Yes | 4 | 4 | ✓ | 88%n=1+tx from settlement history blended with transcripts | – |
| Wegovy | Yes | 4 | 4 | ✓ | 79%n=1+tx from settlement history blended with transcripts | – |
| Canada / Canadian | Yes | 4 | 4 | ✓ | 78%transcripts from the transcript model | – |
| Collaboration | Yes | 3 | 3 | ✓ | 71%n=4+tx from settlement history blended with transcripts | – |
| Perimenopause / Menopause | Yes | 2 | 2 | ✓ | 90%transcripts from the transcript model | – |
| FDA | Yes | 2 | 2 | ✓ | 89%n=4+tx from settlement history blended with transcripts | – |
| Lab Testing | Yes | 1 | 1 | ✓ | 90%n=4+tx from settlement history blended with transcripts | – |
| Longevity | No | 0 | 0 | ✓ | 87%n=1+tx from settlement history blended with transcripts | – |
| Zava | No | 0 | 0 | ✓ | 66%n=4+tx from settlement history blended with transcripts | – |
| Europe | No | 0 | 0 | ✓ | 64%n=4+tx from settlement history blended with transcripts | – |
| Cancer | No | 0 | 0 | ✓ | 40%n=3+tx from settlement history blended with transcripts | – |
| Microdose / Microdosing | No | 0 | 0 | ✓ | 18%n=3+tx from settlement history blended with transcripts | – |
| Galen | No | 0 | 0 | ✓ | 17%transcripts from the transcript model | – |
| Amazon | No | 0 | 0 | ✓ | 16%n=4+tx from settlement history blended with transcripts | – |
| Regulation | No | 0 | 0 | ✓ | 15%n=4+tx from settlement history blended with transcripts | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Nov 9, 2026 02:04 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
4 matches for “Foundayo”; 4 quoted, at least 25 words apart.
…announced agreement, we will expand access to Lilly's GLP-1 medications, Zepbound and Foundayo, offering customers a seamless experience across the full assortment of their weight…
…unlocks an experience that will allow our subscribers to more seamlessly access Foundayo and Zepbound. We also expect our partnership with Novo to continue to…
…quarter will center on broadening our platform's weight loss assortment, inclusive of Foundayo and Zepbound. As we enter the new year, we are excited to…
…fourth quarter, expanding the assortment with the new Lilly partnership to include Foundayo, Zepbound, and then CagriSema once available, that just gives us a broader…
Where the listed words were said
…Later this month, we expect to launch the first phase of our peptide offering that includes sermorelin, glutathione, and NAD+. We plan to add BPC-157…
…clock, that infrastructure positions us to launch treatments of increasing complexity, including testosterone replacement therapy this quarter and our Peptides+ offering later this month. Our…
…bring together the best clinical expertise, diagnostics, prescription medications, daily insights from wearables, supplements, and other tools that support how someone lives every day. What…
…in our international markets. In key regions like the U.K., Germany, and Australia, we are consolidating our brands under Hims & Hers, and we will…
Since closing Eucalyptus in June, we've moved quickly. Hers now live in the U.K. and Australia, serving customers in hair, menopause, and weight loss, and…
…at higher price points than our historical offerings. The introduction of the Wegovy pill from our partnership with Novo has brought an immense amount of…
…early signs of the same dynamic in our weight loss specialty in Canada, where generic options became available earlier this year. Average monthly orders have…
…helps them find what is right for them. In the U.S., our collaboration with Novo reignited growth in our weight loss specialty. We are now…
…$1 billion of revenue this year, as specialties such as dermatology and menopause continue to scale alongside weight loss. Testosterone continues to progress towards achieving…
…terminology, but essentially right now, we're in a comment period where the FDA has put out the proposed ruling from HHS, and we expect in…
…The team has been actively building the guardrails, the clinical standards, the lab testing for this as well, led by Dr. Anant, our Hims Chief…
Agents: this page as TSV at /api/v1/appearances/hims:2026-11-09:earnings_call · words: /api/v1/brief?appearance=hims:2026-11-09:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP